SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

NCT03363555 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

DRUG: SHR-1210

Sponsor

Jiangsu HengRui Medicine Co., Ltd.